A Comparative Evaluation of a MPS Dressing and a CMC Dressing on Subjects With Lower Extremity Venous Ulcers
A Comparative Evaluation of a Marine Polysaccharide (MPS) Dressing and a Carboxymethylcellulose (CMC) Dressing on Subjects With Lower Extremity Venous Ulcers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Keri Joregenson, MBA
- Phone Number: 8476433616
- Email: kajoregenson@medline.com
Study Contact Backup
- Name: Taylor Graef
- Email: Tgraef@medline.com
Study Locations
-
-
California
-
Fresno, California, United States, 93720
- Valley Vascular Surgery Associates
-
Selma, California, United States, 93662
- Central Valley Vein and Wound Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Boston Medical Center
-
-
Michigan
-
Saginaw, Michigan, United States, 48602
- Covenant Hospital
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Baptist Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject is able and willing to comply with requirements of this trial protocol
- Voluntarily signed informed consent before any trial related procedures are performed
- Subjects must be able to communicate effectively with study personnel
- Subject has lower extremity venous ulcer wound, as determined by site PI.
- Subject has adequate circulation as determined by biphasic or triphasic Doppler waveform, consistent with adequate blood flow, within three months prior to study enrollment. If monophasic on exam, then non-invasive tests must display Ankle Brachial Index over 0.8 and no worse than mild disease on segmental pressures.
- Subjects should not be allergic to silver (Ag).
- Size of subject's wound is between 1 squared centimeter and 100 squared centimeters.
- Duration of subject's wound is less than 52 weeks.
Exclusion Criteria:
- Subjects who are pregnant, nursing, or planning to become pregnant during the course of the study.
- Subjects who have known allergies to any ingredient(s) in the clinical products used in this study.
- Subjects who do not wish to use products derived from shellfish.
- Subjects with substance use disorder.
- Subjects with active infection or currently receiving antibiotic treatment.
- Subjects who are currently enrolled in another research study which includes investigational treatment and/or medication.
- Subjects judged by the investigator or sub-investigator to be inappropriate as a subject of this study.
- Subject has previous or current systemic disease(s) which, in the judgement of the site PI, is likely to interfere with the study. However, subjects with well-controlled diabetes mellitus (HbA1C < 8.5) shall be permitted.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Marine polysaccharide dressing
|
The MPS-Ag dressing used in this study has a unique gelling action which helps to remove dead, damaged, and infected tissues from the wound by trapping and removing them later at dressing changes.
It is designed to provide intimate contact with the wound for gentle healing.
It also contains ionic silver.
|
|
Active Comparator: Carboxymethylcellulose dressing
|
The CMC-Ag dressing used in this study incorporates two technologies to help eliminate the key barriers to healing that are exudate, infection, and bioburden.
It can be used on chronic and acute wounds that are infected or at risk of infection with varying exudate levels.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent Change in Wound Size From Baseline
Time Frame: Baseline to 56 days
|
Evaluate and compare the percent change in wound size from first to last visit; therefore, percentage change in wound area (mean (t-test) and median (Mann-Whitney U-test)) from first to last visit was calculated for comparison
|
Baseline to 56 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of Peri-ulcer Skin Assessment Scale
Time Frame: Baseline to 56 days
|
peri-ulcer skin assessment scale is used for assessment.
There are 9 systemically items edema, erythema, white atrophy, venous pigmentation, papulovesicular erythema, hyperkeratosis, purpuric patches, telengiectasis, & itching lesions.
Each is measured for an extension score 0-4 (0=none; 1=punctual, no extension; 2=local, no extension, does not include total ulcer perimeter; 3=includes total ulcer perimeter, does not include spread beyond; 4=spreads beyond total ulcer perimeter) & severity score from 0-3 (=-none; 1=only detected following examination; 2=clearly apparent; 3=as evident as the wound).
The global score is the extension score multiplied by the severity score.
Global scores are added together to a total score.
Total score scale range 0 - 70 with 0 being the best score and 70 being the worst.
All sub-score values, 0 is best score; higher values indicate worsening wounds.
|
Baseline to 56 days
|
|
Score on a Pain Scale.
Time Frame: Baseline to 56 days
|
Pain was assessed at each dressing change over the course of the study on a scale of 0-10 with 0 being no pain and 10 being the worst pain.
The pain score reported was the average of all scores taken at each dressing change for all patients from baseline to 56 days.
|
Baseline to 56 days
|
|
Change in Surface Area of the Dressing
Time Frame: Baseline to 56 days
|
Baseline to 56 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MED-2018-DIV71-026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.